目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T3971 | CDK STAT Ras | ||
CASIN (Pirl1-related Compound 2) 是选择性GTPase Cdc42抑制剂,IC50值是 2 uM。 | |||
T27617 | P450 | ||
Inz-1 是一种有效的真菌特异性线粒体细胞色素 bc1 抑制剂,对酵母和人类的 IC50 分别为 8.092 和 45.320 μM。 Inz-1 可逆转氟康唑或其他三唑类抗真菌药对致病性真菌白色念珠菌的耐药性。 | |||
T2620 | Apoptosis FLT c-RET TAM Receptor Aurora Kinase | ||
G-749 是一种新型 FLT3 抑制剂,对 FLT3 野生型和突变体有持续的抑制作用,IC50值分别为 0.4 nM 和 0.6 nM。它可用于急性髓系白血病的耐药研究。 | |||
T16339 | Calcium Channel P-gp Drug Metabolite | ||
Norverapamil hydrochloride (D591 hydrochloride) 是 Verapamil 的 N-去甲基代谢物,是 L 型钙通道阻滞剂和 P-糖蛋白 (P-gp) 功能抑制剂。 | |||
T15168 | Others | ||
DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 displays perfect anticancer activity against a panel of human cancer cell lines including multi-drug resistance (MDR) phenotype. | |||
T6018 | P-gp | ||
Zosuquidar trihydrochloride (LY-335979 trihydrochloride) 是一种P-糖蛋白抑制剂,Ki 值为 59 nM。 | |||
T6287 | P-gp | ||
Tariquidar (XR9576) 是一种特异性有效的P-糖蛋白抑制剂,Kd 为 5.1 nM。 | |||
T7861 | Bcr-Abl PDGFR c-Kit | ||
Flumatinib mesylate (HHGV678 mesylate) 是一种具有口服活性的选择性Bcr-Abl 抑制剂,能够作用于 c-Abl (IC50:1.2 nM),PDGFRβ (IC50:307.6 nM) 和 c-Kit (IC50:665.5 nM)。 | |||
T3S2381 | Others Antibacterial | ||
Perillene (3-Isohexenylfuran) 是促进肠蠕动的药物中的活性成分,它对金黄色葡萄球菌和大肠杆菌具有很强的抗药性。 | |||
T0002 | Prostaglandin Receptor | ||
Ethamsylate (Dicynene) 通常用作止血药,增加毛细血管内皮阻力和血小板粘附,抑制前列腺素的生物合成和作用。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-05850 | CEACAM6 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), also known as nonspecific crossreacting antigen (NCA) and CD66c, is one of seven human CEACAM family members within the immunoglobulin superfamily. It s a glycosylphosphatidylinositol-linked immunoglobulin superfamily member that is overexpressed in a variety of human cancers, including colon, breast and lung and is associated with tumourigenesis, tumour cell adhesion, invasion and metastasis. CEACAM6 is a unique mediator of migration and invasion of drug resistant oestrogen-deprived breast cancer cells, and this protein could be an important biomarker of metastasis. CEACAM6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.
|
|||||
TMPY-00971 | CEACAM6 Protein, Human, Recombinant (His) | Human | HEK293 | ||
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), also known as nonspecific crossreacting antigen (NCA) and CD66c, is one of seven human CEACAM family members within the immunoglobulin superfamily. It s a glycosylphosphatidylinositol-linked immunoglobulin superfamily member that is overexpressed in a variety of human cancers, including colon, breast and lung and is associated with tumourigenesis, tumour cell adhesion, invasion and metastasis. CEACAM6 is a unique mediator of migration and invasion of drug resistant oestrogen-deprived breast cancer cells, and this protein could be an important biomarker of metastasis. CEACAM6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.
|
|||||
TMPY-02412 | ENO1 Protein, Human, Recombinant (His) | Human | E. coli | ||
The ENO1 gene encodes a multifunctional enzyme that has been identified as a key component of the glycolytic pathway. ENO1 overexpression and post-translational modifications could be of diagnostic and prognostic value in many cancer types. The results of the ENO1 expression profiling of ovarian follicles suggest that ENO1 may play an important dual role in the progress of follicular development, where ENO1 acts as a glycolytic enzyme and also mediates apoptosis. ENO1 overexpression could make the primary culture follicle granulosa cells in vitro improve progesterone secretion. The over-expression of ENO1 protein can enhance the abilities of proliferation and migration in gastric cancer cells of AGS, which indicates that ENO1 may be an important potential tumor-marker associated with the development of gastric cancer. ENO1 and GPI can be used as markers of human sperm freezability before starting the cryopreservation procedure. The inhibition of ENO1 expression may be a novel strategy for therapy for NHLs patients, and it may be a target for drug resistance.
|
|||||
TMPK-00410 | AXL Protein (Primary Amine Labeling), Human, Recombinant (hFc), Biotinylated | Human | HEK293 | ||
Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers.
|
|||||
TMPK-00408 | AXL Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers.
|
|||||
TMPH-01711 | ABCC1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs by decreasing accumulation of drug in cells, and by mediating ATP- and GSH-dependent drug export. Hydrolyzes ATP with low efficiency. Catalyzes the export of sphingosine 1-phosphate from mast cells independently of their degranulation. Participates in inflammatory response by allowing export of leukotriene C4 from leukotriene C4-synthezing cells.
|
|||||
TMPK-00472 | AXL Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers.
|
|||||
TMPK-00407 | AXL Protein, Human, Recombinant (His & Avi) | Human | HEK293 | ||
Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers.
|
|||||
TMPK-00875 | CD96 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
|
|||||
TMPJ-01145 | ABCB5 Protein, Human, Recombinant (Trx) | Human | E. coli | ||
ATP-binding cassette sub-family B member 5(ABCB5) is a plasma membrane-spanning protein. ABCB5 is principally expressed in physiological skin and human malignant melanoma. ABCB5 has been suggested to regulate skin progenitor cell fusion and mediate chemotherapeutic drug resistance in stem-like tumor cell subpopulations in human malignant melanoma. It is commonly over-expressed on circulating melanoma tumour cells. Furthermore, the ABCB5+ melanoma- initiating cells were demonstrated to express FLT1 (VEGFR1) receptor tyrosine kinase which was functionally required for efficient xenograft tumor formation, as demonstrated by shRNA knockdown experiments.
|
|||||
TMPJ-00922 | DCK Protein, Human, Recombinant (His & T7) | Human | E. coli | ||
Deoxycytidine Kinase (DCK) is a member of the DCK/DGK family. DCK exists as a homodimer and is localized to the nucleus. DCK is required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG), and deoxyadenosine (dA). DCK has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. In addition, DCK is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents. DCK is clinically important because of its relationship to drug resistance and sensitivity.
|
|||||
TMPY-03416 | TNFAIP8 Protein, Human, Recombinant (His) | Human | E. coli | ||
Tumor necrosis factor (TNF)-alpha-induced protein 8 (TNFAIP8) family is a newly identified protein with vital roles in maintaining immune homeostasis. Tumor necrosis factor-alpha-inducible protein 8 (TNFAIP8) is a TNF-alpha inducible anti-apoptotic protein with multiple roles in tumor growth and survival. by the creation of cellular autophagy events, TNFAIP8 promotes cell survival and drug resistance in prostate cancer cells. TNFAIP8 regulates Hippo pathway through interacting with LATS1 to promote cell proliferation and invasion in lung cancer. TNFAIP8 may serve as a candidate biomarker for poor prognosis and a target for new therapies.
|
|||||
TMPH-03008 | ENR Protein, Mycobacterium tuberculosis, Recombinant (His) | Mycobacterium tuberculosis | E. coli | ||
Enoyl-ACP reductase of the type II fatty acid syntase (FAS-II) system, which is involved in the biosynthesis of mycolic acids, a major component of mycobacterial cell walls. Catalyzes the NADH-dependent reduction of the double bond of 2-trans-enoyl-[acyl-carrier protein], an essential step in the fatty acid elongation cycle of the FAS-II pathway. Shows preference for long-chain fatty acyl thioester substrates (>C16), and can also use 2-trans-enoyl-CoAs as alternative substrates. The mycobacterial FAS-II system utilizes the products of the FAS-I system as primers to extend fatty acyl chain lengths up to C56, forming the meromycolate chain that serves as the precursor for final mycolic acids.; Is the primary target of the first-line antitubercular drug isoniazid (INH) and of the second-line drug ethionamide (ETH). Overexpressed inhA confers INH and ETH resistance to M.tuberculosis. The mechanism of isoniazid action against InhA is covalent attachment of the activated form of the drug to the nicotinamide ring of NAD and binding of the INH-NAD adduct to the active site of InhA. Similarly, the ETH-NAD adduct binds InhA.
|
|||||
TMPY-04241 | LDHA Protein, Rat, Recombinant (His) | Rat | E. coli | ||
LDHA (Lactate Dehydrogenase A) is a Protein Coding gene. The protein encoded by this gene catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA, a key enzyme regulating aerobic glycolysis, belongs to the lactate dehydrogenase family and is overexpressed in many human cancers, and correlates with poor clinical outcomes. LDHA can promote the Warburg effect to produce lactate and Adenosine Triphosphate (ATP) in aerobic conditions, which contributes to oncogenesis metastasis and drug resistance in various cancers. Up-regulation of lactate dehydrogenase LDHA is a frequent event in human malignancies and relate to poor postoperative outcome. Diseases associated with LDHA include Fanconi-Bickel Syndrome and Myoglobinuria.
|
|||||
TMPY-00010 | LDHA Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
LDHA (Lactate Dehydrogenase A) is a Protein Coding gene. The protein encoded by this gene catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. LDHA, a key enzyme regulating aerobic glycolysis, belongs to the lactate dehydrogenase family and is overexpressed in many human cancers, and correlates with poor clinical outcomes. LDHA can promote the Warburg effect to produce lactate and Adenosine Triphosphate (ATP) in aerobic conditions, which contributes to oncogenesis metastasis and drug resistance in various cancers. Up-regulation of lactate dehydrogenase LDHA is a frequent event in human malignancies and relate to poor postoperative outcome. Diseases associated with LDHA include Fanconi-Bickel Syndrome and Myoglobinuria.
|
|||||
TMPY-05460 | CEACAM6 Protein, Human, Recombinant (His), Biotinylated | Human | HEK293 | ||
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), also known as nonspecific crossreacting antigen (NCA) and CD66c, is one of seven human CEACAM family members within the immunoglobulin superfamily. It s a glycosylphosphatidylinositol-linked immunoglobulin superfamily member that is overexpressed in a variety of human cancers, including colon, breast and lung and is associated with tumourigenesis, tumour cell adhesion, invasion and metastasis. CEACAM6 is a unique mediator of migration and invasion of drug resistant oestrogen-deprived breast cancer cells, and this protein could be an important biomarker of metastasis. CEACAM6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.
|
|||||
TMPY-06758 | CEACAM6 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), also known as nonspecific crossreacting antigen (NCA) and CD66c, is one of seven human CEACAM family members within the immunoglobulin superfamily. It s a glycosylphosphatidylinositol-linked immunoglobulin superfamily member that is overexpressed in a variety of human cancers, including colon, breast and lung and is associated with tumourigenesis, tumour cell adhesion, invasion and metastasis. CEACAM6 is a unique mediator of migration and invasion of drug resistant oestrogen-deprived breast cancer cells, and this protein could be an important biomarker of metastasis. CEACAM6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.
|
|||||
TMPY-06760 | CEACAM6 Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), also known as nonspecific crossreacting antigen (NCA) and CD66c, is one of seven human CEACAM family members within the immunoglobulin superfamily. It s a glycosylphosphatidylinositol-linked immunoglobulin superfamily member that is overexpressed in a variety of human cancers, including colon, breast and lung and is associated with tumourigenesis, tumour cell adhesion, invasion and metastasis. CEACAM6 is a unique mediator of migration and invasion of drug resistant oestrogen-deprived breast cancer cells, and this protein could be an important biomarker of metastasis. CEACAM6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.
|
|||||
TMPY-06836 | NR3C1 Protein, Human, Recombinant (His) | Human | E. coli | ||
NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1) is a Protein Coding gene. This gene encodes glucocorticoid receptor, which can function both as a transcription factor that binds to glucocorticoid response elements in the promoters of glucocorticoid responsive genes to activate their transcription, and as a regulator of other transcription factors. NR3C1 is a transcriptional regulator of many drug-metabolizing enzymes and anti-inflammatory molecules. NR3C1 polymorphisms associate with obesity, muscle strength, and cortisol sensitivity. Glucocorticoid receptor gene polymorphism (NR3C1 646 C>G) may play an important role in the development of severe bronchial asthma and resistance to glucocorticoids (GCs). Disturbances in the structure and function of the glucocorticoid receptor (GR) alter the glucocorticoid regulation of the corticotropin-releasing hormone, which leads to nonspecific activation of numerous receptors in the brain and alters the metabolism.
|
|||||
TMPY-00073 | ENO1 Protein, Rat, Recombinant (His) | Rat | E. coli | ||
The ENO1 gene encodes a multifunctional enzyme that has been identified as a key component of the glycolytic pathway. ENO1 overexpression and post-translational modifications could be of diagnostic and prognostic value in many cancer types. The results of the ENO1 expression profiling of ovarian follicles suggest that ENO1 may play an important dual role in the progress of follicular development, where ENO1 acts as a glycolytic enzyme and also mediates apoptosis. ENO1 overexpression could make the primary culture follicle granulosa cells in vitro improve progesterone secretion. The over-expression of ENO1 protein can enhance the abilities of proliferation and migration in gastric cancer cells of AGS, which indicates that ENO1 may be an important potential tumor-marker associated with the development of gastric cancer. ENO1 and GPI can be used as markers of human sperm freezability before starting the cryopreservation procedure. The inhibition of ENO1 expression may be a novel strategy for therapy for NHLs patients, and it may be a target for drug resistance.
|
|||||
TMPY-02216 | S100P Protein, Human, Recombinant | Human | E. coli | ||
Protein S100-P, also known as Protein S100-E, S100 calcium-binding protein P, S100P and S100E, is a nucleus and cytoplasm protein that belongs to the S-100 family. S100P / S100E contains twoEF-hand domains. S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. S100P / S100E overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. S100P / S100E may directly confer resistance to chemotherapy. S100P / S100E induction may be considered an important step in the initial stage of lung adenocarcinomas, whereas its downregulation in advanced stages seems to be important for tumour progression in which DNA methylation and/or feedback transcription processes play a critical role. S100P / S100E plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Interference with S100P / S100E may provide a novel approach for treatment of pancreatic cancer. S100P / S100E could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone-refractory and metastatic prostate cancer.
|
|||||
TMPY-04944 | S100P Protein, Human, Recombinant, Biotinylated | Human | E. coli | ||
Protein S100-P, also known as Protein S100-E, S100 calcium-binding protein P, S100P and S100E, is a nucleus and cytoplasm protein that belongs to the S-100 family. S100P / S100E contains twoEF-hand domains. S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. S100P / S100E overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. S100P / S100E may directly confer resistance to chemotherapy. S100P / S100E induction may be considered an important step in the initial stage of lung adenocarcinomas, whereas its downregulation in advanced stages seems to be important for tumour progression in which DNA methylation and/or feedback transcription processes play a critical role. S100P / S100E plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Interference with S100P / S100E may provide a novel approach for treatment of pancreatic cancer. S100P / S100E could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone-refractory and metastatic prostate cancer.
|
|||||
TMPY-01576 | Artemin Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 | ||
Artemin (ARTN) is a member of glial cell line-derived neurotrophic factor (GDNF) family of ligands, and its signaling is mediated via a multi-component receptor complex including the glycosylphosphatidylinositol-anchored GDNF family receptors a (GFRa1, GFRa3) and RET receptor tyrosine kinase. The major mechanism of ARTN action is via binding to a non-signaling co-receptor. The major function of ARTN is to drive the molecule to induce migration and axonal projection from sympathetic neurons. It also promotes the survival, proliferation and neurite outgrowth of sympathetic neurons in vitro. ARTN triggers oncogenicity and metastasis by the activation of the AKT signaling pathway. Recent studies have reported that the expression of ARTN in hepatocellular carcinoma is associated with increased tumor size, quick relapse and shorter survival. Furthermore, ARTN promotes drug resistance such as antiestrogens, doxorubicin, fulvestrant, paclitaxel, tamoxifen and trastuzumab. Moreover, ARTN also stimulates the radio-therapeutic resistance. Hypoxia has been reported to regulate the cancer stem cell (CSC) population yet the underlying mechanism is poorly characterized. Artemin (ARTN) is a member of the glial cell derived neurotrophic factor family of ligands, is a hypoxia-responsive factor and is essential for hypoxia-induced CSC expansion in hepatocellular carcinoma (HCC). Clinically, elevated expression of ARTN in HCC was associated with larger tumor size, faster relapse and shorter survival. In vitro, HCC cells with forced expression of ARTN exhibited reduced apoptosis, increased proliferation, epithelial-mesenchymal transition (EMT) and enhanced motility. Additionally, ARTN dramatically increased xenograft tumor size and metastasis in vivo. Moreover, ARTN also enhanced tumorsphere formation and the tumor initiating capacity of HCC cells, consequent to expansion of the CD133+ CSC population. ARTN transcription was directly activated by hypoxia-induced factor-1α (HIF-1α) and hypoxia induced ARTN promoted EMT and increased the CSC population via AKT signaling.
|
|||||
TMPY-02072 | HSF1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Heat shock factor protein 1, also known as heat shock transcription factor 1, HSF1, and HSTF1, is a cytoplasm and nucleus protein that belongs to the HSF family. HSF1 is the major transcription factor of HSPs (heat shock proteins) in response to various stresses. Wild type HSF1 (heat shock transcriptional factor 1) is normally inactive. HSF1 / HSTF1 is a DNA-binding protein that specifically binds heat shock promoter elements (HSE) and activates transcription. In higher eukaryotes, HSF is unable to bind to the HSE unless the cells are heat shocked. HSF1 / HSTF1 protects cells and organisms against various types of stress, either by triggering a complex response that promotes cell survival or by triggering cell death when stress-induced alterations cannot be rescued. HSF1 / HSTF1 is the key protein in regulating the stress response. It can be activated under heat, oxidative, or other stress conditions. Dominant-positive and dominant-negative HSF1 are two types of HSF1 mutants. Both of them gain DNA binding activity in the absence of stress. Also, dominant-positive HSF1 acquires transcriptional activity, which dominant-negative HSF1 does not acquire. HSF1 / HSTF1 was also reported to contribute to cell resistance against genotoxic stress, such as that caused by doxorubicin, an anticancer drug in common clinical use.
|
|||||
TMPY-00827 | CD50 Protein, Human, Recombinant (His & hFc) | Human | HEK293 | ||
The protein ICAM-3, also known as CD50, is a member of the intercellular adhesion molecule (ICAM) family consisting of three members. It is a DC-SIGN ligand that is constitutively expressed on resting leukocytes and is thus an important molecule for the first immune response. ICAM-3 comprises five immunoglobulin-like domains and binds LFA-1 through its two N-terminal domains. It functions not only as an adhesion molecule but also as a potent signaling molecule. ICAM-3 binds to LFA-1 on antigen-presenting cells (APC) stabilizing the T cell-APC interaction, facilitating signaling through the CD3/TCR complex. However, recent evidence using cultured and transformed T cells suggests ICAM-3 may also function in signaling. It has been reported that the CD50 molecule can play a role in developing functionally mature T lymphocytes and its expression increases during the maturation process of T lymphocytes. Also, the interactions of ICAM-3 and LFA-1 facilitate HIV-1- induced virological synapse formation between T cells. ICAM-3 is associated with an increase in cellular radio-resistance and cancer cell proliferation. It could be considered as a candidate for anti-cancer drug development and as a cancer diagnostic marker.
|
|||||
TMPY-01430 | CD50 Protein, Human, Recombinant (His) | Human | HEK293 | ||
The protein ICAM-3, also known as CD50, is a member of the intercellular adhesion molecule (ICAM) family consisting of three members. It is a DC-SIGN ligand that is constitutively expressed on resting leukocytes and is thus an important molecule for the first immune response. ICAM-3 comprises five immunoglobulin-like domains and binds LFA-1 through its two N-terminal domains. It functions not only as an adhesion molecule but also as a potent signaling molecule. ICAM-3 binds to LFA-1 on antigen-presenting cells (APC) stabilizing the T cell-APC interaction, facilitating signaling through the CD3/TCR complex. However, recent evidence using cultured and transformed T cells suggests ICAM-3 may also function in signaling. It has been reported that the CD50 molecule can play a role in developing functionally mature T lymphocytes and its expression increases during the maturation process of T lymphocytes. Also, the interactions of ICAM-3 and LFA-1 facilitate HIV-1- induced virological synapse formation between T cells. ICAM-3 is associated with an increase in cellular radio-resistance and cancer cell proliferation. It could be considered as a candidate for anti-cancer drug development and as a cancer diagnostic marker.
|